ScienceOpen:
research and publishing network
For Publishers
Discovery
Metadata
Peer review
Hosting
Publishing
For Researchers
Join
Publish
Review
Collect
My ScienceOpen
Sign in
Register
Dashboard
Blog
About
Search
Advanced search
My ScienceOpen
Sign in
Register
Dashboard
Search
Search
Advanced search
For Publishers
Discovery
Metadata
Peer review
Hosting
Publishing
For Researchers
Join
Publish
Review
Collect
Blog
About
46
views
0
references
Top references
cited by
3
0 reviews
Review
0
comments
Comment
0
recommends
+1
Recommend
0
collections
Add to
0
shares
Share
Twitter
Sina Weibo
Facebook
Email
2,812
similar
All similar
Record
: found
Abstract
: not found
Article
: not found
Four-in-one antibodies have superior cancer inhibitory activity against EGFR, HER2, HER3 and VEGF through disruption of HER/MET crosstalk
Author(s):
S Hu
,
W Fu
,
W Xu
,
J Takamizawa
,
H Konishi
,
K Yanagisawa
,
S Tomida
,
H Osada
,
H Endoh
Publication date:
2014
Journal:
Cancer Res.
Read this article at
ScienceOpen
Publisher
PubMed
Bookmark
There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.
Related collections
Journal of the ASEAN Federation of Endocrine Societies
Author and article information
Journal
DOI::
10.1158/0008-5472
PubMed ID::
15172979
ScienceOpen disciplines:
Endocrinology & Diabetes
,
Medicine
,
Uncategorized
Data availability:
ScienceOpen disciplines:
Endocrinology & Diabetes
,
Medicine
,
Uncategorized
Comments
Comment on this article
Sign in to comment
scite_
Similar content
2,812
Discovery of AZD8931, an Equipotent, Reversible Inhibitor of Signaling by EGFR, HER2, and HER3 Receptors
Authors:
Robert Bradbury
,
Teresa Klinowska
,
George Kirk
…
Corrigendum: Targeting HER3 to overcome RGFR TKI resistance in NSCLC
Authors:
Qiuqiang Chen
,
Gang Jia
,
Xilin Zhang
…
Patritumab Deruxtecan (HER3-DXd), a Human Epidermal Growth Factor Receptor 3–Directed Antibody-Drug Conjugate, in Patients With Previously Treated Human Epidermal Growth Factor Receptor 3–Expressing Metastatic Breast Cancer: A Multicenter, Phase I/II Trial
Authors:
Ian E. Krop
,
Norikazu Masuda
,
Toru Mukohara
…
See all similar
Cited by
3
MicroRNA-320a promotes 5-FU resistance in human pancreatic cancer cells
Authors:
Weibin Wang
,
Lijun Zhao
,
Xueju Wei
…
Monoclonal Antibodies against the MET/HGF Receptor and Its Ligand: Multitask Tools with Applications from Basic Research to Therapy
Authors:
Maria Prat
,
Francesca Oltolina
,
Cristina Basilico
MicroRNAs: nova classe de reguladores gênicos envolvidos na função endócrina e câncer
Authors:
Júlio Ricarte Filho
,
Edna Kimura
See all cited by